Continuing Medical Education Information
AACE Endocrine University
Event start date: 02/22/2024
Credit claim deadline: 12/31/2024
Statement of Need
Endocrine University® is designed to provide a forum for endocrinology fellows -in-training to enhance their endocrine curriculum, particularly in diabetes, thyroid, bone, and new technology which has become essential to the practice of endocrinology.
Target Audience:
This program is intended for first year Endocrine Fellows-in-Training.
Learning Objectives
By the end of the meeting, participants will be able to:
- Effectively utilize new skills and technology in diabetes and thyroid ultrasound.
- Apply the most up-to-date guidelines and evidence-based practices for the diagnosis and treatment of diabetes and thyroid disease.
- Integrate the latest evidence-based research for diagnosis and treatment of emerging areas of diabetes, thyroid, and bone related practice.
Accreditation and Designation Statements
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology (ACE) designates this other (live virtual) activity for a maximum of 16 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support
This activity is supported by educational grants from the following:
- Abbott Diabetes Care
- Dexcom
- Vertex Pharmaceuticals Inc
- Corcept Therapeutics
- Insulet Corporation
- Medtronic
- Novo Nordisk
- Radius Health
- Ultragenyx Pharmaceutical
- Lilly USA, LLC
- Recordati Rare Diseases
Disclosure and Conflicts of Interest Policy:
The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
Planning Committee Disclosures
Planner Name
Sara E. Lubitz, MD, FACE
Ineligible Company
Ascendis
Eli Lilly
Hologic
Takeda
Amryt
Relevant Financial Relationship
Site PI Research funding
Stock Ownership
Stock Ownership
Site PI Research Funding
Site PI Research Funding
Planner Name
Matthew J. Levine, MD, FACE
Ineligible Company
Mannkind
Recordati
Novo Nordisk
Relevant Financial Relationship
Consultant
Consultant
Speakers Bureau
Planner Name
Geetha Gopalakrishnan, MD, FACE
Ineligible Company
Medtronic
Sparrow and Spruce
Relevant Financial Relationship
Research Funding
Research Funding
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Faculty Disclosures
Faculty Name
Guillermo Umpierrez, MD, MACP, CDCES, FACE
Ineligible Company
Abbott
American Diabetes Association
AstraZeneca
Bayer
Dexcom
Glycare
Relevant Financial Relationship
Research Funding
BOD/EC
Research Funding
Research Funding
Research Funding
Consultant
Faculty Name
Silvio Inzucchi, MD
Ineligible Company
Abbott
AstraZeneca
Boehringer-Ingelheim
Esperion
Lexicon
Merck/Pfizer
Novo Nordisk
VTV Therapeutics
Relevant Financial Relationship
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Faculty Name
William Polonsky, PhD, CDE
Ineligible Company
Abbott Diabetes Care
Dexcom
Sanofi
Embecta
Relevant Financial Relationship
Research Funding
Research Funding
Consultant
Consultant
Faculty Name
Dace Trence, MD, MACE
Ineligible Company
Medtronic
Sanofi
Relevant Financial Relationship
Stock Ownership
Stock Ownership
Faculty Name
Richard E. Pratley, MD
Ineligible Company
Bayer AG
Corcept Therapeutics Inc.
Dexcom
Gasherbaum Bio, Inc.
Hanmi Pharmaceutical Co.
Hengrui (USA) Ltd.
Merck
Metavention
Novo Nordisk
Pfizer
Rivus Pharmaceuticals Inc.
Sanofi
Scohia Pharma Inc.
Sun Pharmaceutical Industries
Relevant Financial Relationship
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Research Funding
Research Funding/Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Faculty Name
Archana Sadhu, MD, FACE
Ineligible Company
Abbott Laboratories
Relevant Financial Relationship
Consultant
Faculty Name
Nadine Palermo, DO
Ineligible Company
Dexcom
Relevant Financial Relationship
Research Funding
Faculty Name
Elias Siraj, MD, FACE, FACP
Ineligible Company
Boehringer-Ingelheim/Eli Lilly alliance
Novo Nordisk
Relevant Financial Relationship
Consultant/Speakers Bureau
Research Funding/Consultant/Speakers Bureau
Faculty Name
David Ahn, MD
Ineligible Company
Ascensia Diabetes Care
Lilly Diabetes
Mannkind
Novo Nordisk
Roche Diagnostics
Xeris Pharmaceuticals
Relevant Financial Relationship
Advisory Board
Advisory Board; Speakers Bureau
Advisory Board
Speakers Bureau
Advisory Board
Speakers Bureau
Faculty Name
Mimi Hu, MD
Ineligible Company
Up To Date
Medullary Thyroid Cancer Consortium Registry
Eli Lilly
Medical Education Resources
Relevant Financial Relationship
Stock Ownership
Stock Ownership
Stock Ownership; Research funding
Stock Ownership
Faculty Name
Trevor Angell, MD
Ineligible Company
Immunovant, Inc.
Relevant Financial Relationship
Research Funding
Faculty Name
Benjamin Gigliotti, MD
Ineligible Company
Immunovant, Inc.
Horizon Pharmaceuticals
Relevant Financial Relationship
Consultant
Consultant
Faculty Name
Raymon H. Grogan, MD
Ineligible Company
Medtronic
Relevant Financial Relationship
Consultant
Faculty Name
Steven Petak, MD, JD, MACE, FACP
Ineligible Company
Alexion
Amgen
Relevant Financial Relationship
Speaker Bureau
Speaker Bureau
Faculty Name
Geetha Gopalakrishnan, MD, FACE
Ineligible Company
Medtronic
Sparrow and Spruce
Relevant Financial Relationship
Research Funding
Research Funding
Faculty Name
Michael Lewiecki, MD, FACE
Ineligible Company
Amgen
Radius
Relevant Financial Relationship
Stock Ownership/Research Funding/Speakers Bureau/Consultant
Stock Ownership/Research Funding
All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Reviewers
None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.